Patients enrolled in the EMPEROR-Preserved trial had more comorbidities, lower EF, and higher NT-proBNP levels than those in other HFpEF studies, such as the PARAGON-HF study [62,63,64]. This evidence concerns the gene NPPB and hydrops fetalis.